Caprock Group, Inc. Neurocrine Biosciences Inc Transaction History

Caprock Group, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	BUY	$130.86 - $143.19 $14,263 - $15,607	109 Added 6.99%	1,669 $229,000
Q1 2024 Apr 29, 2024	BUY	$130.4 - $143.74 $203,424 - $224,234	1,560 New	1,560 $215,000
Q3 2018 Oct 17, 2018	SELL	$98.88 - $125.85 $268,162 - $341,305	-2,712 Closed	0 $0
Q2 2018 Jul 23, 2018	SELL	$75.3 - $105.99 $828 - $1,165	-11 Reduced 0.4%	2,712 $266,000
Q1 2018 Apr 23, 2018	BUY	$75.88 - $92.43 $206,621 - $251,686	2,723 New	2,723 $226,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Caprock Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Caprock Group, Inc. with notifications on news.